Adnexal Neoplasm

cancer family

Identifier: CI-CAN-00000005
Entity page: /cancer/adnexal-neoplasm ↗
Edges: 3,465

Neighbours: 20 genes15 drugs10 trials
Drawn: 45 of 45 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Adnexal Neoplasm approved for …APPROVED_FORderived6 of 6
← approved for	Gemcitabinesmall molecule FDA (US) · approved · 2025-06-27 · in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of plati…	—	approved	Malignant Ovarian Neoplasm	1	Regulatory	openfda	graph →
← approved for	Cyclophosphamide

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

BRCA1 Mutation Olaparib35 active / 82 trials
Curatedlevel Asensitivity· support 4civicObservedBRCA1 altered in 12% (37 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA1 Mutation Rucaparib2 active / 16 trials
Curatedlevel Asensitivity· support 4civicObservedBRCA1 altered in 12% (37 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA2 Mutation Rucaparib2 active / 16 trials
Curatedlevel Asensitivity· support 4civicObservedBRCA2 altered in 11% (34 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA2 Mutation Olaparib35 active / 82 trials
Curatedlevel Asensitivity· support 3civicObservedBRCA2 altered in 11% (34 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm
KRAS Mutation Binimetinib2 active / 2 trials
Curatedlevel Bsensitivity· support 1civicObservedKRAS altered in 32% (38 / 119 cases)no approval record in this cancercontext: Malignant Ovarian Serous Tumor
BRCA1 Loss-of-function Olaparib35 active / 82 trials
Curatedlevel Bsensitivity· support 1civicObservedBRCA1 altered in 12% (37 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA1 Loss-of-function Talazoparib4 active / 11 trials
Curatedlevel Bsensitivity· support 1civicObservedBRCA1 altered in 12% (37 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA1 Mutation Cediranib5 active / 17 trials
Curatedlevel Bsensitivity· support 1civicObservedBRCA1 altered in 12% (37 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Adnexal Neoplasm altered in cohorts of …ALTERED_INderived20 of 20show fewer
← altered in cohorts of	TP53 373 / 523 cases (71 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 5 cohorts	—	—	High-Grade Serous Ovarian Cancer	5	Observed	cbioportal	graph →
← altered in cohorts of	KRAS 38 / 119 cases (32 %) · ssm · lgsoc_mapk_msk_2022	—	—	Low-Grade Serous Ovarian Cancer	1	Observed	cbioportal	graph →
← altered in cohorts of	TTN 110 / 523 cases (21 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 4 cohorts	—	—	High-Grade Serous Ovarian Cancer	4	Observed	cbioportal	graph →
← altered in cohorts of	BRCA1 37 / 316 cases (12 %) · ssm · ov_tcga_pub	—	—	High-Grade Serous Ovarian Cancer	1	Observed	cbioportal	graph →
← altered in cohorts of	BRCA2 34 / 316 cases (11 %) · ssm · ov_tcga_pub	—	—	High-Grade Serous Ovarian Cancer	1	Observed	cbioportal	graph →
← altered in cohorts of	FLG2 41 / 523 cases (7.8 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 2 cohorts	—	—	High-Grade Serous Ovarian Cancer	2	Observed	cbioportal	graph →
← altered in cohorts of	MUC16 41 / 523 cases (7.8 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 2 cohorts	—	—	High-Grade Serous Ovarian Cancer	2	Observed	cbioportal	graph →
← altered in cohorts of	CSMD3 38 / 523 cases (7.3 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 2 cohorts	—	—	High-Grade Serous Ovarian Cancer	2	Observed	cbioportal	graph →
← altered in cohorts of	HMCN1 34 / 523 cases (6.5 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 2 cohorts	—	—	High-Grade Serous Ovarian Cancer	2	Observed	cbioportal	graph →
← altered in cohorts of	USH2A 32 / 523 cases (6.1 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 4 cohorts	—	—	High-Grade Serous Ovarian Cancer	4	Observed	cbioportal	graph →
← altered in cohorts of	AHNAK2 30 / 523 cases (5.7 %) · ssm · ov_tcga_pan_can_atlas_2018	—	—	High-Grade Serous Ovarian Cancer	1	Observed	cbioportal	graph →
← altered in cohorts of	FLG 30 / 523 cases (5.7 %) · ssm · ov_tcga_pan_can_atlas_2018	—	—	High-Grade Serous Ovarian Cancer	1	Observed	cbioportal	graph →
← altered in cohorts of	NF1 30 / 523 cases (5.7 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 2 cohorts	—	—	High-Grade Serous Ovarian Cancer	2	Observed	cbioportal	graph →
← altered in cohorts of	FAT3 23 / 405 cases (5.7 %) · ssm · hgsoc_tcga_gdc	—	—	High-Grade Serous Ovarian Cancer	1	Observed	cbioportal	graph →
← altered in cohorts of	MACF1 29 / 523 cases (5.5 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 2 cohorts	—	—	High-Grade Serous Ovarian Cancer	2	Observed	cbioportal	graph →
← altered in cohorts of	SI 22 / 405 cases (5.4 %) · ssm · hgsoc_tcga_gdc	—	—	High-Grade Serous Ovarian Cancer	1	Observed	cbioportal	graph →
← altered in cohorts of	RYR2 28 / 523 cases (5.4 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 2 cohorts	—	—	High-Grade Serous Ovarian Cancer	2	Observed	cbioportal	graph →
← altered in cohorts of	AHNAK 21 / 405 cases (5.2 %) · ssm · hgsoc_tcga_gdc	—	—	High-Grade Serous Ovarian Cancer	1	Observed	cbioportal	graph →
← altered in cohorts of	APOB 21 / 405 cases (5.2 %) · ssm · hgsoc_tcga_gdc	—	—	High-Grade Serous Ovarian Cancer	1	Observed	cbioportal	graph →
← altered in cohorts of	MUC17 21 / 405 cases (5.2 %) · ssm · hgsoc_tcga_gdc	—	—	High-Grade Serous Ovarian Cancer	1	Observed	cbioportal	graph →

Adnexal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 227show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 324 trials (68 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	324	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 298 trials (57 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	298	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 179 trials (73 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	179	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 93 trials (41 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	93	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 92 trials (24 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	92	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 90 trials (13 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	90	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 84 trials (23 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	84	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 82 trials (35 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	82	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 79 trials (19 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	79	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 75 trials (19 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	75	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 63 trials (21 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	63	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 46 trials (4 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	46	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 43 trials (1 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 36 trials (13 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 35 trials (15 active) · roll-up of the cancer and its descendants	—	—	Adnexal Neoplasm	35	Observed	clinicaltrials	graph →

Adnexal Neoplasm studied in …STUDIED_INderived10 of 3,212show all (up to 200)
→ studied in	NCT00043472completed Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk · condition mapped CURATED_EXACT · 3,212 trials mapped (885 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01247597recruiting DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study · condition mapped ONTOLOGY_EXACT · 3,212 trials mapped (885 active)	—	—	Ovarian Sertoli-Leydig Cell Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT01441089recruiting Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis · condition mapped CURATED_EXACT · 3,212 trials mapped (885 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · condition mapped CURATED_EXACT · 3,212 trials mapped (885 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03762733enrolling by invitation Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies · condition mapped CURATED_EXACT · 3,212 trials mapped (885 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04065009Phase 3 · active not recruiting The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer · condition mapped CURATED_BROADER · 3,212 trials mapped (885 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04789694Phase 3 · recruiting Prehabilitation in Gynaecological Cancer Patients · condition mapped CURATED_EXACT · 3,212 trials mapped (885 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ONTOLOGY_EXACT · 3,212 trials mapped (885 active)	—	—	Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 3,212 trials mapped (885 active)	—	—	Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05867251Phase 1/Phase 2 · recruiting Study of AVZO-021 in Patients With Advanced Solid Tumors · condition mapped ALIAS · 3,212 trials mapped (885 active)	—	—	Malignant Fallopian Tube Neoplasm	1	Observed	clinicaltrials	graph →